Recursion Pharmaceuticals (RXRX) investor relations material

Strategic focus and value drivers

• Emphasis on advancing a diversified pipeline with five clinical programs expecting data in the next 12–18 months, including one entering a registrational trial.

• Platform, partnerships, and internal pipeline are integrated, with all efforts aimed at developing differentiated therapeutics for patients.

• AI and proprietary data (over 50 PB) are leveraged to improve drug discovery success rates and reduce clinical trial failures.

• Partnerships with major pharma companies generate significant milestone payments and support capital efficiency.

• Expense management post-merger led to a 35% budget reduction, with a focus on high-impact programs and disciplined capital allocation.

Technology and innovation

• Full-stack AI-enabled drug discovery platform integrates multimodal biology, chemistry, and patient data to address complex clinical trial failure points.

• Recent publication in Nature Biotechnology demonstrated predictive modeling in cell lines using multimodal data, advancing the concept of a virtual cell.

• Proprietary, highly annotated datasets enable more predictive models than large, poorly annotated public datasets.

• The company’s approach allows for rapid, data-driven trial design and patient selection, improving enrollment rates by 30–50%.

Pipeline highlights

• FAP program (4881) showed a 50% reduction in polyp burden within three months, with durable effects post-treatment; pivotal trial discussions ongoing with the FDA.

• Real-world data and AI-driven analysis inform trial design and FDA engagement, supporting endpoints like polyp burden, excisional burden, and quality of life.

• RBM39 program targets oncology via a novel degrader mechanism, with early PK/PD data meeting expectations and broader data readout expected in the second half of the year.

• Mutant-selective PI3K inhibitor (7735) demonstrates high selectivity and aims to address safety issues like hyperglycemia, with IND-enabling data anticipated.